唑来膦酸治疗恶性肿瘤骨转移疼痛的临床研究

The Clinical Study of Zoledronic Acid in Treating Metastatic Bone Pain of Malignancy

目的:观察唑来膦酸治疗恶性肿瘤骨转移疼痛的疗效和安全性。方法:53例患者随机分为治疗组和对照组,治疗组(26例)采用唑来膦酸4mg加入生理盐水50mL静脉滴注15min以上;对照组(27例)采用帕米膦酸二钠90mg加入生理盐水500mL静脉滴注6h,两组均一次性给药后观察28d。结果:治疗组和对照组总有效率分别为65.38%和62.65%,疗效无显著性差异,P>0.05;不良反应主要为发热、头痛、恶心呕吐、乏力等,均较轻微。结论:唑来膦酸是新一代骨吸收抑制剂,对恶性肿瘤骨转移所致疼痛有较好的临床疗效,不良反应较少,具有使用更方便的优势。

Objective：To investigate the effect and safety of zoledrunic acid in the treatment of pain caused by malignant tumor osseous metastasis. Methods：53 cases were randomly into two groups. The experimented group （26 cases） was treated intravenously by 4 mg zoledronic acid for 15 minutes on the first day; the control group （27 cases） was treated intravenously by 90 mg pamidrunate for 6 hours. The patients were followed up for 28 days to assess the efficacy and safety. Results： The response rate of zoledronic acid and pamidronate was 65.38% and 62.65%, respectively. The toted response rate between the two groups was no statistical difference. The main side effects were fever, headache, nausea, vomiting, and debilitation, no severe adverse events were found. Conclusion：Zoledronic acid is effective and safe in the treatment of patient with metastatic bone pain of malignancy.